Literature DB >> 15189754

Development and validation of the insulin treatment satisfaction questionnaire.

Roger T Anderson1, Soren E Skovlund, David Marrero, Douglas W Levine, Keith Meadows, Meryl Brod, Rajesh Balkrishnan.   

Abstract

BACKGROUND: Treatment of diabetes mellitus (DM) is complex, requiring multifaceted lifestyle change or regulation and, for many, self-regulation of insulin levels in the blood. Historically, daily insulin treatment has been viewed as burdensome to patients, prompting newer formulations and improved delivery methods.
OBJECTIVE: This multicenter, clinical study was designed to develop a conceptually sound, clinically meaningful, and psychometrically valid measure of insulin treatment satisfaction, applicable to a wide range of insulin therapies.
METHODS: A 3-phase iterative process was employed to develop and validate the Insulin Treatment Satisfaction Questionnaire (ITSQ): (1) conceptual development of items, (2) preliminary validation among patients with DM, and (3) confirmatory validation among patients with DM.
RESULTS: The ITSQ was validated with 170 patients in phase 2 and 402 patients in phase 3. Confirmatory factor analysis produced a 5-factor, 22-item instrument assessing regimen inconvenience, lifestyle flexibility, glycemic control, hypoglycemic control, and satisfaction with the insulin delivery device. Results for reliability and construct validity of the final version were consistent in both samples of patients treated with insulin, with different data collection methods. Internal consistency (using Cronbach alpha coefficient) of the subscales ranged from 0.79 to 0.91. Test-retest reliability (using Spearman rank correlation coefficients) ranged from 0.63 to 0.94. ITSQ scores showed moderate to high correlation with related measures of treatment burden. The ITSQ differentiated among insulin delivery methods, glycosylated hemoglobin values, the number of times the patient required assistance administering insulin, and insulin adherence.
CONCLUSION: In our study samples, the ITSQ appeared to be conceptually and psychometrically sound and applicable to a wide range of insulin therapies.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15189754     DOI: 10.1016/s0149-2918(04)90059-8

Source DB:  PubMed          Journal:  Clin Ther        ISSN: 0149-2918            Impact factor:   3.393


  46 in total

1.  Development and Testing of the Insulin Treatment Experience Questionnaire (ITEQ).

Authors:  Jörn Moock; Franz Hessel; Diana Ziegeler; Thomas Kubiak; Thomas Kohlmann
Journal:  Patient       Date:  2010-03-01       Impact factor: 3.883

2.  [Treatment satisfaction].

Authors:  Julia Villar López; Luis Lizán Tudela; Javier Soto Alvarez; Salvador Peiró Moreno
Journal:  Aten Primaria       Date:  2009-08-05       Impact factor: 1.137

3.  Development and validation of the Patient Experience with Treatment and Self-management (PETS): a patient-reported measure of treatment burden.

Authors:  David T Eton; Kathleen J Yost; Jin-Shei Lai; Jennifer L Ridgeway; Jason S Egginton; Jordan K Rosedahl; Mark Linzer; Deborah H Boehm; Azra Thakur; Sara Poplau; Laura Odell; Victor M Montori; Carl R May; Roger T Anderson
Journal:  Qual Life Res       Date:  2016-08-26       Impact factor: 4.147

4.  Reliability and validity of an instrument for assessing patients' perceptions about medications for diabetes: the PAM-D.

Authors:  Patrick O Monahan; Kathleen A Lane; Risa P Hayes; Colleen A McHorney; David G Marrero
Journal:  Qual Life Res       Date:  2009-07-16       Impact factor: 4.147

5.  Scoring and psychometric properties of the Eye-Drop Satisfaction Questionnaire (EDSQ), an instrument to assess satisfaction and compliance with glaucoma treatment.

Authors:  Antoine Regnault; Muriel Viala-Danten; Hélène Gilet; Gilles Berdeaux
Journal:  BMC Ophthalmol       Date:  2010-02-01       Impact factor: 2.209

6.  Development and validation of the Treatment Related Impact Measure of Weight (TRIM-Weight).

Authors:  Meryl Brod; Mette Hammer; Nana Kragh; Suzanne Lessard; Donald M Bushnell
Journal:  Health Qual Life Outcomes       Date:  2010-02-05       Impact factor: 3.186

7.  Patient treatment satisfaction after switching to NovoMix® 30 (BIAsp 30) in the IMPROVE™ study: an analysis of the influence of prior and current treatment factors.

Authors:  Meryl Brod; Paul Valensi; Joseph A Shaban; Don M Bushnell; Torsten L Christensen
Journal:  Qual Life Res       Date:  2010-07-04       Impact factor: 4.147

8.  Diabetes Medication Satisfaction Tool: a focus on treatment regimens.

Authors:  Roger T Anderson; Cynthia J Girman; Manjiri D Pawaskar; Fabian T Camacho; Jorge Calles; William S Kelly; Carla DeMuro; Rajesh Balkrishnan
Journal:  Diabetes Care       Date:  2008-10-17       Impact factor: 19.112

9.  Correlates of insulin injection omission.

Authors:  Mark Peyrot; Richard R Rubin; Davida F Kruger; Luther B Travis
Journal:  Diabetes Care       Date:  2010-02       Impact factor: 19.112

10.  Understanding and assessing the impact of treatment in diabetes: the Treatment-Related Impact Measures for Diabetes and Devices (TRIM-Diabetes and TRIM-Diabetes Device).

Authors:  Meryl Brod; Mette Hammer; Torsten Christensen; Suzanne Lessard; Donald M Bushnell
Journal:  Health Qual Life Outcomes       Date:  2009-09-09       Impact factor: 3.186

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.